Patents by Inventor Roger H. Unger

Roger H. Unger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120108503
    Abstract: The present invention provides for methods of treating type I diabetes by inducing hyperleptinemia in subjects afflicted with type I diabetes. These methods can achieve normoglycemia and suppress hypergluconemia, and alleviate conditions associated with such, even in the absence of or at extremely low levels of adjunct insulin therapy, and without any appreciable increase in insulinogenesis.
    Type: Application
    Filed: August 20, 2009
    Publication date: May 3, 2012
    Inventor: Roger H. Unger
  • Patent number: 6171856
    Abstract: The present invention relates to methods and compositions for the treatment of diabetes involving free radicals. In particular, the present invention is directed to the treatment or prophylactic intervention of diabetes. The present invention demonstrates that MnSOD can play a protective role against cytokine killing, and provides strategies for engineering cell lines as islet surrogates for transplantation therapy of diabetes mellitus. Further, the present invention shows that &bgr;-cell destruction and dysfunction in adipogenic diabetes is mediated via fatty acids. Methods and compositions for ameliorating this disorder are provided herein.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: January 9, 2001
    Assignees: Board of Regents, The University of Texas System, Betagene, Inc
    Inventors: Anice Thigpen, Hans-Ewald Hohmeier, Christopher B. Newgard, Roger H. Unger, Michio Shimabukuro, Guoxun Chen, Christopher J. Rhodes, Sigrun R. H{umlaut over (u)}gl, Sharon Cousin
  • Patent number: 6004759
    Abstract: Disclosed are compositions and methods for diagnosing autoimmune insulin dependent diabetes mellitus. In general, diagnostic methods of the invention include testing for the presence of an autoimmune immunoglobulin in a suspected patient's serum wherein the immunoglobulin is identified by its ability to interfere with the glucose transporting activity of a pancreatic islet cell glucose transporter. The inventors have discovered that the presence of such an autoimmune antibody in patient's serum is diagnostic of autoimmune insulin dependant diabetes mellitus. In particular aspects the diagnostic assay of the invention involves the incubation of isolated and dispersed islet cells, such as rat islet cells, in the presence of immunoglobulin obtained from the patient. Following such an incubation, the islet cells are tested for their ability to uptake glucose. A diagnosis is made through a determination that immunoglobulins in the serum of the patient specifically inhibit the uptake of glucose by the islet cells.
    Type: Grant
    Filed: October 6, 1992
    Date of Patent: December 21, 1999
    Assignee: Board of Regents, The University of Texas System
    Inventors: John H. Johnson, Roger H. Unger
  • Patent number: 5175085
    Abstract: Disclosed are compositions and methods for diagnosing autoimmune insulin dependent diabetes mellitus. In general, diagnostic methods of the invention include testing for the presence of an autoimmune immunoglobulin in a suspected patient's serum wherein the immunoglobulin is identified by its ability to interfere with the glucose transporting activity of a pancreatic islet cell glucose transporter. The inventors have discovered that the presence of such an autoimmune antibody in patient's serum is diagnostic of autoimmune insulin dependent diabetes mellitus. In particular aspects the diagnostic assay of the invention involves the incubation of isolated and dispersed islet cells, such as rat islet cells, in the presence of immunoglobulin obtained from the patient. Following such an incubation, the islet cells are tested for their ability to uptake glucose. A diagnosis is made through a determination that immunoglobulins in the serum of the patient specifically inhibit the uptake of glucose by the islet cells.
    Type: Grant
    Filed: February 20, 1990
    Date of Patent: December 29, 1992
    Assignee: Board of Regents, The University of Texas System
    Inventors: John H. Johnson, Roger H. Unger